SCOTTSDALE, Ariz., April 19 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today the initiation of a Phase II clinical trial for their proprietary lead development compound MTR 104, a low molecular weight isothiourea derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension.
The Phase II trial of MTR 104 is for Intradialytic Hypotension (IDH). This Phase II double blind clinical trial, under U. S. FDA IND No 66505, will involve chronic renal failure (CRF) patients who experience IDH.
Meditor Ltd. will be moving forward in conducting additional clinical trials in chronic indications such as Migraine.
Meditor Ltd. has retained VCG & Associates, Inc. (VCG&A) to evaluate offers from pharmaceutical manufacturers having the potential to develop and commercialize MTR 104 in the above selected therapeutic categories.
For all inquiries please contact Michael Schultz, R.Ph. managing partner with VCG & Associates, Inc. at 636-329-1452. This press release is also available by fax 24 hours a day at no charge by calling 1-636-329-1452. www.vcgassociates.com
Meditor is an Israel based pharmaceutical development company founded to develop and commercialize a class of compounds called Nitric Oxide Synthase Inhibitors. The lead development compound is MTR 104. The patent portfolio of Meditor provides the company with a strong proprietary position in the U.S. and worldwide.
VCG & Associates, Inc. (VCG&A) is an independent strategic marketing organization specializing in the commercialization of pharmaceuticals, diagnostics and devices for small to medium size late stage pharmaceutical and healthcare companies.
VCG & Associates, Inc.
CONTACT: Michael Schultz, R.Ph., managing partner of VCG & Associates,Inc., +1-636-329-1452